To ban the sale of nitrous oxide consumer products, and for other purposes.

HR7945 was introduced on March 16, 2026 by Rep. Kevin Mullin (D-CA-15) and referred to the House Committee on Energy and Commerce. The bill would classify any consumer product containing nitrous oxide as a banned hazardous product under the Consumer Product Safety Act, effective 180 days after enactment. However, Section 2(b) explicitly exempts N2O used in medical/dental treatment, commercial food production, commercial kitchens, and any consumer food product where N2O is used as a propellant to drive food out of a pressurized container. This last exemption covers virtually all consumer food aerosol products (whipped cream dispensers, cooking sprays, etc.). No funding is authorized or appropriated by this bill — it is purely a product safety regulation. Because of the broad food propellant exemption, major food and beverage companies like Kraft Heinz ($KHC), PepsiCo ($PEP), Coca-Cola ($KO), Mondelez ($MDLZ), J.M. Smucker ($SJM), and General Mills ($GIS) face zero structural impact. The bill targets recreational N2O products (e.g., 'whippits' sold for recreational inhalation), not food-grade products. No publicly traded US companies have material revenue exposure to standalone recreational nitrous oxide consumer products; these are primarily sold by small specialty retailers and importers. Real market data shows $KHC at $22.46 (30-day change -0.13%), $PEP at $156.57 (+0.82%), $KO at $78.63 (+3.39%), $MDLZ at $61.30 (+6.35%), $SJM at $97.28 (+0.87%), and $GIS at $34.60 (-7.04%). These movements are consistent with sector-wide trends and earnings narratives — there is no evidence of any bill-related volatility. The bill has seen zero legislative action since referral, has only two sponsors total, and has not been scheduled for committee markup. Remaining legislative path: The bill must pass through the Energy and Commerce Committee, then the full House, then the Senate, and be signed by the President. With committee assignment to a low-priority docket and minimal bipartisan support, the probability of enactment in the 119th Congress is negligible. No companion Senate bill exists.